Costs versus benefits of biological therapy and current utilization profile
Keywords:
health care costs, biological products, biological therapyAbstract
Introduction: Biological therapy is one of the latest pharmacological innovations in therapeutic regimens for various conditions. Its benefits are indisputable; however, its costs, adverse events, and utilization profiles merit further analysis.
Objective: To analyze the cost-benefit ratio of biological therapy as well as its current utilization profile.
Development: A cost-benefit analysis of biological therapy was conducted, taking into account its main etiopathogenic mechanisms, adverse events, and economic costs. Its main indication profiles were also studied based on their pharmacokinetic characteristics and the feasibility of incorporating them into the basic medication regimens of public health institutions in Ecuador.
Conclusions: Biological drugs offer advantages related to the selectivity of therapeutic targets and the control of the inflammatory process. However, their high cost, the high rate of serious adverse events, and access barriers pose significant challenges in terms of health equity and sustainability for the Ecuadorian health system.
Downloads
References
1. Dallo I, Etcheto HF, Collazo C, Chahla J, Gobbi A. Terapias biológicas en artroscopía de rodilla. De las ciencias básicas a la aplicación clínica [Internet]. Revista Artroscopia Educ Med Súper. 2020 [acceso: 02/09/2024]; 27(3):136-45. Disponible en: https://revistaartroscopia.com.ar/index.php/revista/article/view/116
2. Quera R, Córdova A, Núñez P, Correa I, Flores L. Utilización de Upadacitinib en el tratamiento de la enfermedad de Crohn: reporte de dos casos clínicos [Internet]. Revista de Gastroenterología del Perú. 2024 [acceso: 02/09/2024]; 44(2):162-6. Disponible en: http://www.scielo.org.pe/scielo.php?pid=S1022-51292024000200162&script=sci_arttext
3. Monforte-Gasque MP, Lázaro-Gallardo EM, Lázaro-Castellano AM, Querol-Hernández AC, Maroto-García E, Borrás-Martí F. Evaluación del dolor en pacientes con patologías reumáticas en tratamiento con terapias biológicas [Internet]. Anales Sis San Navarra. 2022 [acceso: 04/09/2024]; 45(3):e1020. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-66272022000300005&lng=es
4. Castillo EJ, Palomeque, DM. Terapia Biológica y Moduladores del Sistema Inmunológico en el tratamiento de las Enfermedades Inflamatorias Intestinales [Internet]. Salud ConCiencia. 2023 [acceso: 01/09/2024]; 2(2):e32. Disponible en: https://saludconciencia.com.ar/index.php/scc/article/view/32
5. Mosquera-Klinger G. Tuberculosis intestinal secundaria a uso de terapia biológica: ¿puede mimetizar la enfermedad de Crohn? [Internet]. Univ Medicina. 2021 [acceso: 03/09/2024]; 62(1):110-7. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S2011-08392021000100011&lng=en
6. Orozco HA, García MB, Girón LN, Pacheco R. Terapia biológica en artritis reumatoidea: una revisión de reacciones adversas [Internet]. Revista Colombiana de Reumatología. 2022 [acceso: 01/09/2024]; 29(4):239-48. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0121812321000876
7. Yamamoto-Furusho JK, Bosques-Padilla FJ, Martínez-Vázquez MA. Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal [Internet]. Revista de Gastroenterología de México. 2021 [acceso: 02/09/2024]; 86(1):70-85. Disponible en: https://www.sciencedirect.com/science/article/pii/S0375090620301324
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Eduardo Xavier Macias Collahuazo, Henry David Vásconez Vásconez, Maryuri Alexandra Zamora Cusme, Víctor Hugo Vásconez Samaniego
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
